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Each session of the 2007 Montagna 
Symposium on the Biology of Skin* 
was organized around a specific dis-
ease, starting with an introduction by 
the Session Chair, an expert in the dis-
ease, and ending with a breakout ses-
sion guided by questions posed by the 
session chairs. (A list of the questions 
addressed and approaches and actions 
determined can be viewed in the 
Supplementary Information online.)
The Symposium began on Thursday 
evening with keynote talks by patient 
advocates from three disease founda-
tions: Victoria Kalabokes (the National 
Alopecia Areata Foundation), Elizabeth 
Horn (the International Psoriasis 
Council), and Judy Jones (the Cutaneous 
Lymphoma Foundation). A particular 
highlight was the participation of Irene 
Crosby, who gave her view as a patient 
with atopic dermatitis. An eye open-
er for many of us was the enormous 
burden that patients carry in order to 
minimize stigmatization by the pub-
lic, including washing bed linens every 
day and always wearing black or dark 
colors so that small blood spots do not 
show (eczema) or never wearing black 
so that skin flakes do not show (psoria-
sis). The advocates explained that many 
patients feel ignored by society, fund-
ing agencies, and doctors who “just 
gave them a tube of something to stop 
the itch.” We also learned that patient-
based organizations not only are active 
in public education, they also support 
research, both financially and by main-
taining databases of individuals willing 
to participate in research studies. The 
important take-home message was that 
researchers should contact these foun-
dations to identify patients to partici-
pate in research studies.
psoriasiform reactions
The highlight of the Symposium 
came from Brian Nickoloff’s opening 
remarks about psoriasis. When asked 
by a patient, “Why can’t you figure 
out what causes this disease?,” he 
answered, “Well, it’s tricky.” He went 
on to explain that you can’t separate 
the epithelium from the immune sys-
tem. He also noted that a family of dis-
eases produce psoriasis-like plaques; 
thus, not all psoriasiform reactions 
mean that the patient has psoriasis 
per se. There are HLA-DR and T-cell 
subset differences. This theme was 
continued by Andrew Blauvelt, who 
described a psoriasis mouse model 
in which TH17 T cells induced kera-
tinocytes to express receptors that 
attracted more TH17 T cells. A con-
tinuous interactive loop was thus 
formed. Kristina Duffin explained that 
psoriasis is also a genetic disease, as 
demonstrated by studies of twins, and 
that a phenotype often runs within a 
family. However, no single gene has 
been found to be causative for this 
disease. Using phenotypic classifica-
tion, she clustered gene loci according 
to risk for psoriasis. Michelle Lowes 
discussed cellular phenotypes with 
psoriasis showing high levels of CD3+, 
HLA-DR+, and CD11c+ cells and low 
levels of BDCA cells. Continuing the 
theme of cellular phenotypes, Thomas 
McCormick demonstrated that T-regu-
latory cells did not function properly 
in psoriatic plaques; i.e., they did not 
suppress proliferation of T-memory/
effector cells. Frank Nestle introduced 
psoriatic mouse models. He made a 
humanized model by grafting unin-
volved psoriatic human skin to Rag 
knockout mice. These formed psori-
atic plaques without additional T cells. 
Karin Scharffetter-Kochanek’s psoriatic 
mouse model was made by knocking 
out CD18, which demonstrated that 
T-regulatory cells were not function-
ing properly, because T-reg cells from 
wild-type mice normalized the skin. 
Nicole Ward concluded the session 
with a short talk about a new mouse 
model made using an inducible TIE2.
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Atopic/spongiotic reactions
In an overview of atopic dermatitis and 
other eczemas, Jon Hanifin informed 
us that atopic dermatitis comes on in 
childhood; that 80% of patients have 
increased IgE levels, which cause 
itching; and that most cases are also 
associated with asthma, hay fever, and 
other allergies, but that 20% are not. 
The current belief is that T cells arrive 
at the behest of the keratinocytes after 
the epidermal barrier has been com-
promised. Shinji Shimada explored 
the role of mast cells that reside in the 
skin. These cells are filled with dense 
granules and react via stimuli through 
Toll-like receptors, which likely cross-
talk with IgE receptors. Julie Segre dis-
cussed the role of the residing local 
bacteria and the fact that different 
areas of the skin show different quan-
tities of various bacteria that affect 
mutual local bacterial colonization. 
Thus, early atopic dermatitis could 
be an adaptive mode in reaction to 
nonsterile outside environs. She also 
mentioned that the understanding of 
the normal and diseased skin micro-
biome is an NIH Roadmap initiative. 
Lisa Beck agreed that atopic derma-
titis could be an adaptive immune 
response but said it may also be an 
innate response. Her data suggest 
that atopic dermatitis may also have 
a genetic effector that may allow bar-
rier compromise to occur. Mihail 
Iordanov explored released cyto-
kines as causal for hyperproliferation 
of keratinocytes.
Lichenoid reactions
As Richard Sontheimer explained 
in his introduction, lichenoid tissue 
reactions (LTRs)/interface dermatitis 
represent a large number of diverse 
skin diseases with scaly plaques that 
are very itchy. They are currently clas-
sified according to the amount of lym-
phocytic infiltrate as cell rich or cell 
poor. The major challenges are that 
these conditions are not common and 
almost everything triggers the reac-
tion. Jan Dutz introduced dendritic 
cells and explained their role in the 
circle of keratinocyte death induced 
by activated T-memory cells, an event 
possibly controlled by regulatory 
T cells. He reviewed several mouse 
models of lichenoid skin disease. A 
classic model was made by inject-
ing autoreactive T-cell clones into the 
footpads of mice. Graft-vs.-host dis-
ease was proposed as a convenient 
model for studying LTRs. Continuing 
with the T-cell model, Jorg Wenzel 
described how T cells target defec-
tive keratinocytes following local type 
I interferon expression in humans. 
Stephan Meller added that local 
cytokines (e.g., the type I interferon, 
IFN-α) induced inflammatory chemo-
kines, such as CXCL family members. 
He proposed that aberrant expression 
of CXCLs could indicate a propensity 
to disease. Miriam Merad presented 
her work on graft-vs.-host disease. 
She used a parabiotic animal model to 
prove that Langerhans cells move into 
the skin from the bone marrow dur-
ing development, but that once there, 
Langerhans cells remain in the skin 
unless the skin is damaged, e.g., in 
lichenoid reactions. In such diseases, 
when the Langerhans cells are dam-
aged or leave, they are replaced from 
the bone marrow. This turnover of 
Langerhans cells is proposed to mod-
ulate subsequent immune reactions.
Cutaneous malignancies
Using mouse models, Stuart Yuspa 
described the inflammatory mediators 
and receptors involved in the induc-
tion and maintenance of cutaneous 
squamous cell carcinoma. Continuing 
with mouse models, Michael Girardi 
examined the role of the immune 
system in spontaneous regression 
of tumors, specifically as related to 
Langerhans cells and different subsets 
of αβ T cells as well as γδ T cells. Sam 
Hwang introduced cutaneous T-cell 
lymphomas (CTCLs) as a rare group of 
diseases of mostly CD4+ T cells with 
yet unknown etiologies. The T cells 
preferentially home to cutaneous sites 
via cell surface chemokine receptors. 
The skin expresses a number of chemo-
kine ligands that can attract T cells via 
these receptors Thus, therapies could 
target the receptors. James Campbell, 
using CCR4 knockout mice in a model 
of antigen-specific T-cell trafficking, 
demonstrated the requirement for the 
CCR4 receptor for homing of T cells 
to the skin. Alain Rook discussed the 
clinical aspects of CTCL, specifically 
introducing the mechanism by which 
several effective biological agents may 
target different aspects of the immune 
system. He emphasized that the 
increasing ability of the dendritic cell 
to present T-cell antigens may be the 
key in stimulating host antilymphoma 
responses in CTCL.
To end the symposium, Carl Baker 
and Cheryl Lapham, Program Directors 
at the National Institute of Arthritis and 
Musculoskeletal and Skin Diseases 
(NIAMS), National Institutes of Health, 
discussed new directions at NIAMS 
and the potential for funding via sever-
al mechanisms, such as K99/R00 and 
the new Roadmap initiatives.
David Norris, from the University 
of Colorado Health Sciences Center, 
showed pictures of past Symposia 
participants and gave a hilarious, fact-
filled talk about what it was like to 
attend the Montagna Symposium first 
as an awe-filled young dermatologist 
and then as its Chair for 13 years. We 
are fortunate that David remains as 
Chair Emeritus. Summing up the heart 
of this long-standing forum on cutane-
ous biology, David was heard to say at 
the Sunday event, “I’ve totally changed 
the way I look at lichenoid disease 
after this session. I sat there thinking, ‘I 
needed to be here.’”
2007 SiD eugene m. Farber travel 
Awards for Young investigators and the 
mSBS Director’s Award
As in the past, we helped nine young 
investigators to attend the Montagna 
Symposium through a generous dona-
tion from the Eugene M. Farber family:
Erin Fitch, BA
Department of Dermatology, Oregon Health & 
Science University, Portland, OR 
“Inducible expression of TGFβ1 in 
basal keratinocytes causes psoriasis-
like disease in transgenic mice: role 
of the IL-23/IL-17 inflammatory path-
way”
Mehran Ghoreishi, MD, PhD
Departments of Dermatology and Medicine, 
University of British Columbia, Vancouver, BC, 
Canada
“Expansion of antigen-specific regula-
tory T cells with the topical vitamin D 
analogue calcipotriol”




Departments of Gene and Cell Medicine,  
Mount Sinai School of Medicine, New York, NY 
“Identification of a langerin express-
ing dermal dendritic cell population 
that differs from migrating epidermal 
Langerhans cells”
Karen Jonscher, PhD
Department of Anesthesiology, University of 
Colorado Health Sciences Center, Denver, CO
“Toward the identification of proteins 
in activated human T cells that drive 
macrophage activation and proin-
flammatory cytokine production”
Daniel Kaplan, MD, PhD
Department of Immunology, University of  
Minnesota, Minneapolis, MN
“Autocrine/paracrine TGFβ is 
required for the development of epi-
dermal Langerhans cells”
Li Li, PhD
Department of Dermatology, University of  
Colorado Health Sciences Center, Denver, CO
“Novel human T cell cytokine induc-
ing surface molecules (TCISMs), 
including CD40 ligand, augments  
T-cell-driven macrophage activation  
to produce proinflammatory  
cytokines”
Anke Lonsdorf, PhD
Dermatology Branch, National Cancer Institute, 
Bethesda, MD
“Accumulation of epidermis-derived 
CCL27 in skin-draining lymph nodes 
following topical application of a 
contact sensitizer induces accumula-
tion of CCR10-positive cells”
Francesca Mascia, PhD
Laboratory of Cancer Biology & Genetics, 
Center for Cancer Research, National Cancer 
Institute, Bethesda, MD
“EGFR activation regulates the expres-
sion of GM-CSF in keratinocytes”
Julie Wolfram, BA
Departments of Dermatology and Pathology, 
Case Western Reserve University, Cleveland, OH
“Keratinocyte-specific overexpres-
sion of the angiopoietin receptor Tie2 
leads to development of a psoriasi-
form phenotype”
One additional fellow was funded 
by an MSBS Director’s Award; Adam 
Giangreco, PhD, Cambridge Research 
Montagna 2008:  
“The Biologic Basis of Psoriasis”
October 2–6, 2008, Salishan Resort, Gleneden Beach, Oregon
Program Chairs: Andrew Blauvelt, MD 
Professor, Departments 
of Dermatology and 
Molecular Microbiology & 
Immunology
Oregon Health & Science 
University
Chief of Dermatology 
Service, Portland VA 
Medical Center
Anne M. Bowcock, PhD
Professor, Departments of 
Genetics, Pediatrics, and 
Internal Medicine
Faculty Director, Human 
and Statistical Genetics 
Program
Washington University in 
St. Louis
Institute, Cambridge, UK: “Necl2 
promotes keratinocyte adhesion and 
targets cells for autoimmune lympho-
cyte-mediated killing”
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SUppLementArY mAteriAL
Breakout Session Questions, Approaches, and 
Actions. Selected topics and conclusions from 
the Montagna Symposium.
*The 56th Annual Montagna Symposium 
on the Biology of Skin was held at 
Salishan Resort, Gleneden Beach, Oregon, 
USA, 11–15 October 2007.
Information about content and 
support of past Symposia and the next 
Montagna Symposium on the Biology 
of Skin can be found at http://www.
montagnasymposium.org.
